NCT06740474View on ClinicalTrials.gov

A Study to Assess the Safety, Tolerability and Pharmacokinetics of ABI-6250 in Healthy Participants

PHASE1RecruitingINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

January 31, 2025

Primary Completion Date

August 31, 2025

Study Completion Date

August 31, 2025

Conditions
Hepatitis Delta VirusHepatitis D
Interventions
DRUG

ABI-6250

Single dose (SAD) or once or twice daily dosing over 10 days (MAD)

DRUG

Placebo

Single dose (SAD) or once or twice daily dosing over 10 days (MAD)

Trial Locations (1)

Unknown

RECRUITING

New Zealand Clinical Research, Auckland

Sponsors
All Listed Sponsors
lead

Assembly Biosciences

INDUSTRY